AstraZeneca and Merck hope new data can PROpel their PARP inhibitor into first-line prostate cancer
Last year, Clovis’ PARP inhibitor Rubraca beat AstraZeneca and Merck’s blockbuster Lynparza across the finish line in prostate cancer by a matter of days. Now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
